Rani Therapeutics Holdings, Inc. Class A Common Stock
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Open RANI dashboard ↗Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also develops surgical robot to enable placement of patient optimized orthopedic implants in the United States. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Open ZBH dashboard ↗